Table 3.
Association of LINE-1 methylation levels with risk of MS and clinical activity.
| OR | IC 95% | p value | |
|---|---|---|---|
| Model 1 (risk of MS): | |||
| Age | 1.063 | 1.004–1.125 | 0.035 |
| Gender (female vs. male) | 2.242 | 0.781–6.438 | n.s. |
| Model 2 (risk of MS): | |||
| LINE-1 methylation levels (high vs. low) | 6.992 | 1.927–24.763 | 0.003 |
| Age | 1.073 | 1.011–1.139 | 0.021 |
| Gender (female vs. male) | 4.456 | 1.222–16.240 | 0.024 |
| Model 3 (clinical activity): | |||
| LINE-1 methylation levels (high vs. low) | 11.046 | 1.605–76.046 | 0.015 |
| Age | 0.939 | 0.865–1.020 | n.s. |
| Gender (female vs. male) | 1.764 | 0.239–13.02 | n.s. |
Dependent variable in model 1 and 2: risk of MS (0: control; 1: non-treated MS patients). Dependent variable in model 3: clinical activity status after one year of treatment (0: without clinical activity; 1: with clinical activity). Low LINE-1 methylation: below the 75th percentile in the control group. High LINE-1 methylation: above the 75th percentile in the control group.